Gadoversetamide (BioDeep_00000614963)
代谢物信息卡片
gadolinium(3+) ion 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
化学式: C20H34GdN5O10 (662.1546674)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]
InChI: /q
描述信息
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
同义名列表
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:31644
- KEGGdrug: D01646
- PubChem: 444013
- Metlin: METLIN85399
- DrugBank: DB00538
- CAS: 131069-91-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hanieh Attari, Yan Cao, Tina R Elmholdt, Yize Zhao, Martin R Prince. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Radiology.
2019 08; 292(2):376-386. doi:
10.1148/radiol.2019182916. [PMID: 31264946] - Lara Chehabeddine, Tala Al Saleh, Marwa Baalbaki, Eman Saleh, Samia J Khoury, Salem Hannoun. Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents.
Critical reviews in toxicology.
2019 03; 49(3):262-279. doi:
10.1080/10408444.2019.1592109. [PMID: 30942117] - John P Prybylski, Richard C Semelka, Michael Jay. The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes.
Magnetic resonance imaging.
2017 05; 38(?):145-151. doi:
10.1016/j.mri.2017.01.006. [PMID: 28089499] - John P Prybylski, Michael Jay. The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.
Advances in chronic kidney disease.
2017 05; 24(3):176-182. doi:
10.1053/j.ackd.2017.03.002. [PMID: 28501081] - Richard C Semelka, Joana Ramalho, Ami Vakharia, Mamdoh AlObaidy, Lauren M Burke, Michael Jay, Miguel Ramalho. Gadolinium deposition disease: Initial description of a disease that has been around for a while.
Magnetic resonance imaging.
2016 Dec; 34(10):1383-1390. doi:
10.1016/j.mri.2016.07.016. [PMID: 27530966] - Jeremy C Durack, Bertrand Richioud, James Lyon, Stephen B Solomon. Late emergence of contrast-enhancing fat necrosis mimicking tumor seeding after renal cryoablation.
Journal of vascular and interventional radiology : JVIR.
2014 Jan; 25(1):133-7. doi:
10.1016/j.jvir.2013.07.006. [PMID: 24365507] - J Haylor, M E Vickers, S K Morcos. Interference of gadolinium-based contrast agents with the measurement of serum creatinine by the Jaffe reaction.
The British journal of radiology.
2009 May; 82(977):438-9. doi:
10.1259/bjr/13806057. [PMID: 19386963] - James H Wible, Prasad N V Tata, Alicia M Napoli, Lisa H Lowe, Gregory L Kearns. Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients.
Magnetic resonance imaging.
2009 May; 27(4):512-8. doi:
10.1016/j.mri.2008.08.002. [PMID: 18814985] - Ralph A Magnotti, Jodi L Connell, Peter M Marietta. Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate.
Clinica chimica acta; international journal of clinical chemistry.
2009 Jan; 399(1-2):59-63. doi:
10.1016/j.cca.2008.09.009. [PMID: 18834869] - Deepak Kadiyala, David A Roer, Mark A Perazella. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2009 Jan; 53(1):133-7. doi:
10.1053/j.ajkd.2008.09.016. [PMID: 19022548] - Alexander J Kallen, Michael A Jhung, Steven Cheng, Theresa Hess, George Turabelidze, Liana Abramova, Matthew Arduino, Jeannette Guarner, Brian Pollack, Georges Saab, Priti R Patel. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2008 Jun; 51(6):966-75. doi:
10.1053/j.ajkd.2007.12.036. [PMID: 18501784] - Mark A Perazella. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?.
Clinical journal of the American Society of Nephrology : CJASN.
2008 May; 3(3):649-51. doi:
10.2215/cjn.00670208. [PMID: 18385396] - Robert F Reilly. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN.
2008 May; 3(3):747-51. doi:
10.2215/cjn.05721207. [PMID: 18287249] - Martin A Sieber, Philipp Lengsfeld, Jakob Walter, Heiko Schirmer, Thomas Frenzel, Fred Siegmund, Hanns-Joachim Weinmann, Hubertus Pietsch. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
Journal of magnetic resonance imaging : JMRI.
2008 May; 27(5):955-62. doi:
10.1002/jmri.21368. [PMID: 18425843] - Manish J Gandhi, Vamsidhar R Narra, Jeffrey J Brown, Amy Guo, Daniel S Grosu, Curtis A Parvin, Mitchell G Scott. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference.
AJR. American journal of roentgenology.
2008 Mar; 190(3):W213-7. doi:
10.2214/ajr.07.2923. [PMID: 18287415] - Peter C Thomson, Tara A Collidge, Patrick B Mark, Jamie P Traynor. Gadolinium contrast may be risky in kidney disease.
BMJ (Clinical research ed.).
2007 Jun; 334(7608):1335-6. doi:
10.1136/bmj.39254.924641.1f. [PMID: 17599982] - Andrea Löwe, Thomas Balzer, Uta Hirt. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.
Investigative radiology.
2005 Aug; 40(8):521-5. doi:
10.1097/01.rli.0000170447.45577.5e. [PMID: 16024990] - James H Wible, Michael R Hynes. Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
Radiology.
2004 Oct; 233(1):158-64. doi:
10.1148/radiol.2331031689. [PMID: 15454620] - Jane Emerson, Gerald Kost. Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value.
Archives of pathology & laboratory medicine.
2004 Oct; 128(10):1151-6. doi:
10.5858/2004-128-1151-shaooo. [PMID: 15387706] - James F Baker, Linda C Kratz, Gary R Stevens, James H Wible. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects.
Investigative radiology.
2004 Jun; 39(6):334-9. doi:
10.1097/01.rli.0000124455.11402.52. [PMID: 15167099] - Hyunseok Peter Kang, Mitchell G Scott, Bonnie N Joe, Vamsi Narra, Jay Heiken, Curtis A Parvin. Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method.
Clinical chemistry.
2004 Apr; 50(4):741-6. doi:
10.1373/clinchem.2003.028886. [PMID: 14962999] - Richard W Katzberg, Marija Ivanovic, Michael H Buonocore, John M Brock, John M Ryan. Cortical, medullary, and pelvocaliceal MR renography with and without diuretic modification.
Academic radiology.
2003 Jul; 10(7):725-38. doi:
10.1016/s1076-6332(03)80118-6. [PMID: 12862282] - Jeffrey J Brown, Rita M Kristy, Gary R Stevens, Joseph A Pierro. The OptiMARK clinical development program: summary of safety data.
Journal of magnetic resonance imaging : JMRI.
2002 Apr; 15(4):446-55. doi:
10.1002/jmri.10091. [PMID: 11948834] - S K Swan, J F Baker, R Free, R M Tucker, B Barron, R Barr, S Seltzer, G S Gazelle, K R Maravilla, W Barr, G R Stevens, L J Lambrecht, J A Pierro. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.
Journal of magnetic resonance imaging : JMRI.
1999 Feb; 9(2):317-21. doi:
10.1002/(sici)1522-2586(199902)9:2<317::aid-jmri25>3.0.co;2-b. [PMID: 10077031]